RecruitingPhase 4NCT06564246
Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease
Sponsor
Tanta University
Enrollment
44 participants
Start Date
Sep 18, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.
Eligibility
Min Age: 17 YearsMax Age: 60 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Vonoprazan 20 mg versus Pantoprazole 40 mg for people with gastroesophageal reflux disease (gerd). The study is currently recruiting participants at 1 location. People eligible for this study include aged 17 Years to 60 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVonoprazan 20 mg versus Pantoprazole 40 mg
Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06564246
Related Trials
Indiana University Gastrointestinal Motility Diagnosis Registry
NCT045065931 location
Esophageal Cancer Risk Registry
NCT002605851 location
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
NCT069844847 locations
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
NCT0261630233 locations
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
NCT058701636 locations